Bold Therapeutics

Bold Therapeutics is a clinical-stage biopharmaceutical company located in Vancouver, British Columbia, founded in 2018 to develop and commercialize BOLD-100, a first-in-class small molecule therapy applicable to oncology and infectious diseases (COVID-19).BOLD-100 is a ruthenium-based small molecule therapeutic that significantly enhances the activity of many other anticancer therapies by disabling critical and previously untargeted cancer survival and proliferation pathways.Based on compelling preclinical and early clinical results, Bold Therapeutics has focused its development efforts on some of the most challenging cancer indications, where existing therapies are largely ineffective, leading to unmet medical needs.